Lipid-modifying agents under development

There are now several agents tailored for improving dyslipidaemic lipid profiles that have passed the preclinical testing and are presently in clinical trials. The two major fields for these new lipid drugs are: 1. To lower the levels of apoB-containing (atherogenic) lipoproteins, i.e. LDL, VLDL and Lp(a). 2. To increase the levels of apoA-containing (protective) lipoproteins, i.e. HDL.